SCHEMBL4742154

SCHEMBL4742154

Cc1cc(NCc2cc(-c3ccc(F)c(F)c3)no2)sn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 6/20 0.48
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.37
MAPT P10636 4/20 0.37
THRB P10828 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 2/20 0.36
CYP1A2 P05177 2/20 0.36
JAK2 O60674 1/20 0.36
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TP53 P04637 1/20 0.35
NOTUM Q6P988 2/20 0.35
TRPV3 Q8NET8 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4684188 0.83 IGF1R (0.41) IGF1RPOLBMAPTSMN1; SMN2
SCHEMBL6429916 0.78 PSEN1 (0.37) IGF1RCYP3A4CYP2C19
SCHEMBL14345150 0.76 PSEN1 (0.38) IGF1RPOLBLMNASMN1; SMN2CYP1A2
SCHEMBL3582885 0.74 IGF1R (0.46) IGF1RPOLBLMNAMAPTTHRB
SCHEMBL4740687 0.73 MAPT (0.37) IGF1RPOLBLMNAMAPTTHRB
SCHEMBL3591952 0.73 POLB (0.72) IGF1RPOLBLMNAMAPTTHRB
SCHEMBL4683349 0.70 NOTUM (0.66) IGF1RPOLBLMNAMAPTTHRB
SCHEMBL4684429 0.70 NOTUM (0.66) IGF1RPOLBLMNAMAPTTHRB
SCHEMBL13844498 0.68 RAB9A (0.46) IGF1RLMNAMAPTTHRBHTT
SCHEMBL4684431 0.66 MAPT (0.57) IGF1RLMNAMAPTTHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 IGF1R 798/4885POLB 1162/4885LMNA 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.